01—Abstract
Summary
Summary of the 10-Q filed August 10, 2016. Cited figures are marked; the original filing is the authoritative source.
TASER International, Inc. (now Axon Enterprise, Inc.) reported solid top-line growth in the second quarter of 2016, with net sales increasing by 25.8% year-over-year to $58.8 milliona.
This growth was primarily driven by a significant 48.7%b increase in the Axon segment's net sales, signaling strong market adoption of their integrated hardware and software solutions, including on-officer cameras and Evidence.com. While the TASER Weapons segment also saw a 20.4% increase in sales, the Axon segment's rapid expansion suggests a successful strategic pivot towards broader law enforcement technology solutions. Despite revenue growth, profitability metrics show a mixed picture.
Gross margin decreased slightly year-over-year, influenced by increased discounting in the TASER Weapons segment and a slight rise in cost of sales in the Axon segment. Furthermore, Sales, General, and Administrative (SG&A) expenses increased substantially, particularly within the Axon segment, due to investments in sales and marketing to support expansion.
Consequently, net income for the quarter declined by approximately 40% to $3.7 millionc, or $0.07 per diluted share, compared to $6.1 million, or $0.11 per diluted share, in the prior year period. Investors should monitor the increasing SG&A as a percentage of sales and the continued growth trajectory of the Axon segment as key indicators for future profitability.
02—Key points
Key Highlights
- Net sales increased by 25.8% to $58.8 million in Q2 2016 compared to Q2 2015.
- The Axon segment experienced robust growth with net sales up 48.7% year-over-year, driven by on-officer cameras and Evidence.com.
- TASER Weapons segment net sales grew by 20.4% year-over-year.
- Gross margin decreased from 65.8% to 63.5% year-over-year due to increased discounting and higher cost of sales.
- SG&A expenses increased significantly by 57.9% year-over-year, primarily due to investments in sales and marketing for the Axon segment.
- Net income decreased by 40% to $3.7 million ($0.07/share) from $6.1 million ($0.11/share) in the prior year period.
- Bookings for the Axon segment saw substantial growth, increasing by 135.2% to $72.0 million in Q2 2016.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2016, Axon Enterprise, Inc. kept $0.06.
- Revenue$58.8M100.0%
- Cost of revenue−$21.5M36.5%
- Gross profit$37.3M63.5%
- Operating costs−$31.1M52.9%
- Operating income$6.2M10.6%
- Interest, other & tax−$2.6M4.4%
- Net income$3.6M6.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2016filed August 10, 2016Financial Statements
Q2 FY2016 against Q2 FY2015
| Line item | Q2 FY2016Q2 FY2015 | Change |
|---|---|---|
| Revenue | $58.76M$46.71M | +25.8% |
| Cost of Revenue | $21.46M$15.99M | +34.2% |
| Gross Profit | $37.30M$30.72M | +21.4% |
| R&D Expenses | $6.71M$5.91M | +13.6% |
| SG&A Expenses | $24.38M$15.44M | +57.9% |
| Operating Expenses | $31.09M$21.35M | +45.6% |
| Operating Income | $6.21M$9.37M | −33.8% |
| Net Income | $3.65M$6.10M | −40.2% |
| EPS (Basic) | $0.07$0.11 | −36.4% |
| EPS (Diluted) | $0.07$0.11 | −36.4% |
| Shares Outstanding (Basic) | 52.48M53.64M | −2.2% |
| Shares Outstanding (Diluted) | 53.29M54.80M | −2.8% |
05—Questions
Frequently Asked Questions
What is driving the significant growth in the Axon segment?
The Axon segment's growth is driven by the increasing adoption of on-officer cameras (like Axon Body and Axon Flex) and the Evidence.com cloud-based digital evidence management software. This integrated approach to evidence capture, storage, and management is resonating well with law enforcement agencies.
Why did net income decrease despite strong sales growth?
The decrease in net income was primarily due to a substantial increase in Sales, General, and Administrative (SG&A) expenses, which rose by 57.9%. This increase was largely driven by investments in expanding the sales and marketing teams, particularly for the growing Axon segment, and increased lobbying efforts. Additionally, a slight decrease in gross margin due to increased discounting in the TASER Weapons segment also contributed.
What is the company's strategy regarding stock repurchases?
The company announced a stock repurchase program in February 2016, authorizing up to $50 million in repurchases. During the second quarter of 2016, the company repurchased approximately 1.3 million shares for $24.8 million. As of June 30, 2016, $16.2 million remained available under this program, indicating a commitment to returning capital to shareholders while managing its cash.
What is the company's approach to managing legal and litigation risks?
TASER International has faced product litigation, primarily related to CEW use. The company has implemented new risk management strategies since 2009, which have effectively reduced the number of active cases. While they generally have a policy against settling suspect injury or death cases, exceptions are made for strategic benefits. They are also involved in other litigation, including patent and contract disputes, and are vigorously defending themselves. The company believes that outstanding litigation will not materially affect its financial condition, though outcomes are uncertain.
06—Continue